IL22 and inflammatory bowel disease: Interleukin-22 (IL-22) has been shown to promote mucosal healing, and to repair epithelial tissue in mouse models, highlighting its potential as a therapeutic agent for diseases with compromised barrier function, including inflammatory bowel disease (IBD).